CA3197916A1 - Compounds and their use in treatment of tachykinin receptor mediated disorders - Google Patents

Compounds and their use in treatment of tachykinin receptor mediated disorders

Info

Publication number
CA3197916A1
CA3197916A1 CA3197916A CA3197916A CA3197916A1 CA 3197916 A1 CA3197916 A1 CA 3197916A1 CA 3197916 A CA3197916 A CA 3197916A CA 3197916 A CA3197916 A CA 3197916A CA 3197916 A1 CA3197916 A1 CA 3197916A1
Authority
CA
Canada
Prior art keywords
nk2r
group
agonist
amino acids
nle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3197916A
Other languages
English (en)
French (fr)
Inventor
Magnus Bernt Fredrik Gustafsson
Johnny Madsen
Olivia MULVAD
Wouter Frederik Johan HOGENDORF
Jakob Bondo HANSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Embark Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embark Biotech ApS filed Critical Embark Biotech ApS
Publication of CA3197916A1 publication Critical patent/CA3197916A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3197916A 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders Pending CA3197916A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206509.0 2020-11-09
EP20206509 2020-11-09
PCT/EP2021/081057 WO2022096736A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Publications (1)

Publication Number Publication Date
CA3197916A1 true CA3197916A1 (en) 2022-05-12

Family

ID=73198203

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3197916A Pending CA3197916A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Country Status (13)

Country Link
US (1) US20230406883A1 (enExample)
EP (1) EP4240749A1 (enExample)
JP (1) JP2023551122A (enExample)
KR (1) KR20230106616A (enExample)
CN (1) CN116745310A (enExample)
AU (1) AU2021374843A1 (enExample)
CA (1) CA3197916A1 (enExample)
CL (1) CL2023001325A1 (enExample)
CO (1) CO2023007404A2 (enExample)
IL (1) IL302745A (enExample)
MX (1) MX2023005408A (enExample)
PE (1) PE20231952A1 (enExample)
WO (1) WO2022096736A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
CN117384258B (zh) * 2023-10-12 2024-07-26 湖南中晟全肽生物科技股份有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660247A3 (en) * 2009-05-08 2014-09-03 Chongxi Yu High penetration prodrug compositions of peptides and peptide-related compounds
CA2918245C (en) * 2013-08-01 2022-08-30 Dignify Therapeutics, Inc. Compositions and methods for inducing urinary voiding and defecation
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
MX392572B (es) * 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
US11352391B2 (en) * 2017-09-21 2022-06-07 Dignify Therapeutics, Llc Compositions for inducing urinary voiding and defecation
PE20210473A1 (es) * 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
KR20220084035A (ko) * 2019-10-17 2022-06-21 유니버시티 오브 코펜하겐 Tacr2의 효능제

Also Published As

Publication number Publication date
PE20231952A1 (es) 2023-12-06
WO2022096736A1 (en) 2022-05-12
US20230406883A1 (en) 2023-12-21
CL2023001325A1 (es) 2023-12-15
MX2023005408A (es) 2023-07-25
AU2021374843A1 (en) 2023-06-08
KR20230106616A (ko) 2023-07-13
AU2021374843A9 (en) 2024-08-08
JP2023551122A (ja) 2023-12-07
CO2023007404A2 (es) 2023-07-10
EP4240749A1 (en) 2023-09-13
IL302745A (en) 2023-07-01
CN116745310A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
US12371465B2 (en) Incretin analogs and uses thereof
JP7450724B2 (ja) インクレチン類似体およびその使用
US11834486B2 (en) Incretin analogs and uses thereof
CN109475592B (zh) 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物
CA2891929C (en) Improved peptide pharmaceuticals
US20230406883A1 (en) Compounds and their use in treatment of tachykinin receptor mediated disorders
US5834428A (en) Glucagon-like peptide-2 and its therapeutic use
KR20210016632A (ko) Gip/glp1 공효능제 화합물
CN104918961A (zh) 用于胰岛素抗性的改良的肽药物
JP7213811B2 (ja) 新規なステープルペプチドおよびその使用
JP2021515759A (ja) コンプスタチン類似体及びその医療用途
WO2007124461A2 (en) Glp-1 compounds
US20240270821A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2023207107A1 (zh) Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途
WO2024022465A1 (zh) 一种人胰淀素多肽衍生物及其用途
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
Niida et al. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives
KR20120052274A (ko) 경점막 흡수성을 가진 모틸린 유사 펩타이드 화합물
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EA049082B1 (ru) Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором
Batra et al. Pneumadin: a new lung peptide which triggers antidiuresis
EP4721754A1 (en) Polypeptide derivative for oral delivery
HK40005282A (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251024

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251024

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251222

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260122

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122